CONFIDENTIAL 0 0 Paul Stoffels, M.D. Chief Scientific Officer Worldwide Chairman, Pharmaceuticals.

Slides:

Advertisements

Similar presentations

The TB Alliance-Bayer Moxifloxacin Deal

Advertisements

The WHO Medicines Strategy Richard Laing Based on materials produced by Hans V. Hogerzeil, Essential Medicines and Pharmaceutical Policies November.

Differential pricing and access to medicines: issues and options Andrew Creese Essential Drugs and Medicines Policy Health Technology and Pharmaceuticals.

TBD-UK: The UK response in the discovery and development of new TB drugs. Dr Geoff Coxon Deputy Leader & Director of Medicinal Chemistry, TBD-UK APPG-TB.

Pharmaceuticals and Global Health: Successes, Challenges and Outlook 19. July 2013, University of Sussex Thomas B. Cueni, Secretary General Interpharma.

TB Drug Co-Development Roundtable: TMC207 (bedaquiline) Chrispin Kambili, M.D. CPTR meeting Oct 04, To edit footers: "insert tab>header and footer"

The Medicines Patent Pool advancing innovation, expanding access, promoting public health Charles Clift Chair, Medicines Patent Pool

NCI Center for Global Health Jo Anne Zujewski, M.D. September 11, 2014 Dar es Salaam, Tanzania.

The role of commercial enterprises in health Dr. Petra Laux, GSK Brussels September 2001.

CFCS grant recipient: AFRO Global Alliance (AGA), Ghana Project: TB Voice Network Advocacy, Communication and Social Mobilization (ACSM) Subgroup Meeting.

HIV, Globilisation and Futures: HIV Clinical trials in a global world Dr Gillian Hales Roche Products.

Slide 2 Key Points Although HIV/AIDS is found throughout the world, most people living with HIV/AIDS reside in low- and middle-income countries More people.

Opportunities & Challenges: Expanding Access to Hepatitis C Treatment Gregg Alton Executive Vice President, Corporate & Medical Affairs.

Update by IDA Foundation Leontien Ruttenberg MSc MBA.

 HIV & AIDS are a very serious threat in Zambia, a poor-resource developing country of 13.5 million inhabitants in sub-Saharan Africa and presents significant.

PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,

 Critical Enablers for HIV, TB & Malaria Responses UNDP & Global Fund informal session 30 th meeting of the Global Fund Board Dr Mandeep Dhaliwal United.

AIM 2030 Access to Innovative Medicines Draft concept for a new World Bank-led multi-stakeholder initiative August 2014, Andreas Seiter.

Total health ODA commitments, US$ Billions.

DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.

Call to governments: Boost innovation for neglected diseases Bernard Pécoul Executive Director MSF meeting 8 June 2005.

Research4Life – a short overview. Background  April 2000 – WHO surveyed developing country researchers to discover their highest information priority.

Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb.

Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.

Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.

Rosalinda E. B. Milla, MD Professor and Dean College of Arts and Sciences United States University.

UK Policy considerations on increasing access to medicines for the poor in developing countries. DEPARTMENT FOR INTERNATIONAL DEVELOPMENT.

TASK FORCE ON RETOOLING STOP TB PARTNERSHIP Cape Town November 2007.

The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.

Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.

MEDICAL INNOVATION March What Are The Public Health Benefits of Medical Innovation? Breakthrough medicines New devices Innovative medical procedures.

Patents and Medicines: How the system has discouraged innovation and reduced patient access to benefits of knowledge GREG PERRY Director General, EGA World.

RETHINKING NEEDS-DRIVEN INNOVATION FROM THE SOUTH Access to Essential Medicines Initiative Seminar Public Health Program – Open Society Foundation (OSF)

Pharmacology & Prescribing Essential Drugs: Practical Guidelines International Drug Price Indicator Guide Merck Manuals WHO Model List of Essential Drugs.

Monitoring UA 2010 in health sector 1 |1 | Monitoring progress towards Universal Access 2010 in the health sector Kevin M De Cock Ties Boerma.

PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCH Towards a more inclusive model.

Traditional Medicine and HIF: Perspectives from India New Delhi May 12 th and 13 th 2011 Sachin Chaturvedi 1.

TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.

Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.

Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.

Alexandra Heumber Médecins Sans Frontières Access to Essential Medicines Campaign DEBRIEFING WHA May 2006.

Meeting of the Working Group on TB Drug Development Why you need to be engaged? Marcos Espinal Executive Secretary Stop TB Partnership 29 October 2004.

HORIZON 2020 SC1-Health, demographic change and wellbeing challenge Марина Николовска Министерство за образование и наука

GLOBAL MARKET TRENDS The view from Pharma By Peter Knauer Executive Partner, Alliance Partnership.

Scaling up access to antiretroviral therapy in low- and middle-income countries: global and regional progress in 2008 Yves Souteyrand HIV/AIDS Department,

The Role of Patents, Universities, and Non-Profits in the Promotion of Health Care Access Nina Gandhi.

3rd WHO Prequalification Stakeholders Meeting :Diagnostics 3rd Stakeholders Meeting on Prequalification Geneva, 4th February 2008 Update on Prequalification.

Rethinking Health Innovation from the South WORKSHOP South Africa/ Cape town December 13 – 15 /2010.

GLOBAL COOPERATION FOR IP AND DEVELOPMENT Esteban Burrone Head of Policy Medicines Patent Pool.

Managing adolescents and young people with HIV: Challenges and Solutions: Introduction Dr. Tajudeen Oyewale, MD, MPH, PhD. HIV Section, UNICEF New York.

2007 Pan American Health Organization 2004 Pan American Health Organization Malaria in the Americas: Progress, Challenges, Strategies and Main Activities.

IMPROVING ACCESS AND INNOVATION IN HIV THROUGH VOLUNTARY LICENSING: THE EXPERIENCE OF THE MEDICINES PATENT POOL ICASA – Harare, Zimbabwe Session on Innovation.

Science for Global Health: Fostering International Research Collaboration James Herrington, PhD, MPH Director Division of International Relations Fogarty.

VOLUNTARY PATENT POOLING FOR PUBLIC HEALTH A Model For Innovation And Access.

3rd International HIV/Viral Hepatitis Co-Infection Meeting HIV/Viral Hepatitis: Improving Diagnosis, Antiviral Therapy and Access Sunday, 17 July.

Number of people receiving antiretroviral therapy in

Overview of Global HIV Epidemic

Daniel Meressa, M.D. Global Health Committee St. Peter’s Hospital

INNOVATION IN THE DEVELOPMENT OF NEW DRUGS AND CREATIVE SOLUTIONS TO ENSURING EARLY AND ENHANCED ACCESS Paul Stoffels, M.D. Chief Scientific Officer,

How does teamwork improve value. Dr Nils E

Work Programme The social challenge “Health, Demographic Change and Wellbeing” Maia Okujava NCP for Health, Demographic Change and weii-being,

Finland, a Global Testbed for Personalized Cancer Research?

Mitch Morris, MD Executive Vice President OptumInsight

Accessing Medicines in Africa Prospects and challenges

Pre-conference Meeting Report

Antiretroviral therapy coverage in sub-Saharan Africa,

22nd International AIDS Conference Amsterdam, 24 July 2018

Paul Stoffels, MD Vice Chairman, Chief Scientific Officer, Johnson & Johnson.

Group One How would we increase the alignment of the SDG’s with The National Development Plan (NDP).

The Global Fund to Fight AIDS, Tuberculosis and Malaria

Presentation transcript:

CONFIDENTIAL 0 0 Paul Stoffels, M.D. Chief Scientific Officer Worldwide Chairman, Pharmaceuticals

CONFIDENTIAL 1 1 A Legacy of Innovation, Grounded in Science Inspired by the legacy of Dr. Paul Janssen in Global Health “Dr. Paul” was a leader in transformational drug development –Discovered 80 new medicines including four listed as essential medicines by the World Health Organization (WHO) A passion for addressing unmet needs for global public health

CONFIDENTIAL 2 2 Global Public Health Advancing global health and well-being requires: Focused, innovative approaches toward science and research & development and Sustainable access to medicines and care 1 2

CONFIDENTIAL 3 3 Focused R&D Innovations Global health challenges in resource-limited settings call for products designed to address specific needs Harness the best science in the world to develop and improve treatments for greatest unmet need including HIV, tuberculosis, and neglected tropical diseases

CONFIDENTIAL 4 4 Developing New Medicines for MDR-TB Bedaquiline: TB drug with a new mechanism of action granted accelerated approval by the U.S., EU, and Korea, for the treatment of pulmonary MDR-TB as part of combination therapy in adults WHO Interim Policy Guidance provides conditions for rational use in low and middle income countries Unprecedented update of the WHO guidelines within six months after FDA approval

CONFIDENTIAL 5 5 Innovating New Solutions for Series Health Challenges through Partnerships “…the first time in 40 years that the agency had approved a drug that attacked tuberculosis in a different way from the current treatments on the market.” F.D.A. Approves Drug for Resistant Tuberculosis

CONFIDENTIAL 6 6 Collaboration with Multiple Stakeholders is Key

CONFIDENTIAL 7 7 Our Global Access & Partnerships Program for HIV Portfolio of 3 HIV treatments: –PREZISTA ® (darunavir) –INTELENCE ® (etravirine) –EDURANT TM (rilpivirine) Focus is sustainable HIV drug access and appropriate use of our medicines in resource- limited countries –Sub-Saharan Africa (SSA) and least developed countries (LDCs) –Lower middle-income countries

CONFIDENTIAL 8 8 Creating Sustainable HIV and MDR-TB Drug Access in Resource-Limited Countries